ABMD 32.79 Abiomed $ABMD Hit a 52 week high of 32.
Post# of 90
Posted On: 11/01/2014 10:03:26 PM
ABMD 32.79 Abiomed $ABMD Hit a 52 week high of 32.99 Closing the day 10/31/14 at 32.79 +1.44 +4.59% With a day low of 31.58 and a total volume of 1,316,100.
ABMD Recent Posts: http://investorshangout.com/Abiomed-ABMD-53201/
ABMD Abiomed Recent Headline News
Nasdaq stocks posting largest percentage increases
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
IMDZ: 30.99 (+1.39), ABMD: 32.79 (+1.44), BGFV: 12.31 (+0.29), RDCM: 8.60 (+0.10), AMED: 26.10 (+0.82), MRCY: 13.98 (-0.07), OMER: 16.57 (unch), ESBF: 18.66 (+0.07), EVOK: 6.70 (+0.76), IQNT: 16.83 (+1.10), KONA: 22.53 (+0.57), TQNT: 21.63 (+1.56), LAKE: 14.10 (-0.14), SAJA: 6.48 (-0.34)
Ocwen Financial Climbs Despite Earnings Shortfall
at The Street - Thu Oct 30, 4:20PM CDT
ABIOMED, Inc. (NASDAQ:ABMD), Calix Inc (NYSE:CALX) and Ocwen Financial Corp (NYSE:OCN) are today's top-gaining billionaire stock picks. In the red this Thursday are Yamana Gold Inc. (NYSE:AUY), Wes...
ABMD: 32.79 (+1.44), CALX: 10.81 (+0.05), OCN: 23.56 (+0.40), AUY: 3.98 (-0.48), WSTL: 1.34 (-0.09)
Abiomed tops Street 2Q forecasts
Automated Insights - Thu Oct 30, 7:28AM CDT
DANVERS, Mass. (AP) _ Abiomed Inc. (ABMD) on Thursday reported profit of $3.8 million in its fiscal second quarter.
ABMD: 32.79 (+1.44)
Abiomed Announces Second Quarter Fiscal 2015 Revenue of $51.9 Million, Up 17% Over Prior Year
GlobeNewswire - Thu Oct 30, 6:10AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reports second quarter fiscal 2015 revenue of $51.9 million, an increase of 17% compared to revenue of $44.3 million for the same period of fiscal 2014. Second quarter fiscal 2015 GAAP net income was $3.8 million or $0.09 per diluted share, compared to GAAP net income of $1.1 million or $0.03 per diluted share for the prior year period.
ABMD: 32.79 (+1.44)
Abiomed Second Quarter Fiscal 2015 Earnings and Conference Call Notification
GlobeNewswire - Thu Oct 09, 1:41PM CDT
Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, October 30, 2014, the Company will release financial results for the second quarter of fiscal 2015. The Company will host a conference call to discuss the results on Thursday, October 30, 2014, at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer; Robert L. Bowen, Vice President and Chief Financial Officer, will host the conference call.
ABMD: 32.79 (+1.44)
ABIOMED Up on Positive Impella RP Clinical Trial Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:02PM CDT
Data gathered at the end of the 30-day trial was encouraging and exhibited the high potential of ABIOMED, Inc.'s (ABMD) Impella RP in the treatment of RVF patients.
ATEC: 1.52 (-0.05), ABMD: 32.79 (+1.44), RTIX: 5.09 (+0.33), ERB: 3.08 (unch)
Abiomed Appoints Ingrid Goldberg as Director of Investor Relations
GlobeNewswire - Thu Sep 18, 9:34AM CDT
Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the appointment of Ingrid Goldberg, as Director of Investor Relations.
ABMD: 32.79 (+1.44)
Clinical Trial Results for Impella RP Right Ventricular Heart Failure Trial, RECOVER RIGHT, Released at TCT 2014
GlobeNewswire - Tue Sep 16, 4:03PM CDT
Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP(TM) (Right Percutaneous) System. The clinical trial results demonstrated a survival rate of 73% in the overall patient population.
ABMD: 32.79 (+1.44)
Data From RECOVER RIGHT Impella RP Trial to be Announced at TCT 2014
GlobeNewswire - Wed Sep 10, 7:39AM CDT
Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced that data from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP(TM) (Right Peripheral) System, will be released during the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2014 scientific meeting.
ABMD: 32.79 (+1.44)
Abiomed to Present at the Morgan Stanley Global Healthcare Conference 2014
GlobeNewswire - Wed Sep 03, 7:08AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on September 10, 2014 at 10:20 a.m. EDT. The conference will be held at the Grand Hyatt New York in New York, NY.
ABMD: 32.79 (+1.44), MS: 34.95 (+0.43)
10.4% Return Seen to Date on SmarTrend ABIOMED Call (ABMD)
Comtex SmarTrend(R) - Wed Aug 27, 11:29AM CDT
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on June 6th, 2014 at $23.28. In approximately 3 months, ABIOMED has returned 10.38% as of today's recent price of $25.69.
ABMD: 32.79 (+1.44)
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
ABMD: 32.79 (+1.44), BDX: 128.70 (+1.18), MDT: 68.16 (+0.73), ARAY: 6.33 (+0.11), NUVA: 40.90 (+1.64), CYBX: 52.50 (+1.77), BSX: 13.28 (+0.10), JNJ: 107.78 (+0.74), ICUI: 70.90 (unch), WMGI: 31.62 (-0.16), OPK: 8.35 (-0.04), RMD: 52.22 (+0.11), ABBV: 63.46 (+2.28), SYK: 87.53 (+0.49), ZMH: 111.24 (+1.96), ABT: 43.59 (+0.10), SMA: 9.90 (+0.16), BCR: 163.97 (+2.98), MCK: 203.41 (-0.07), TMO: 117.57 (+0.98), PFE: 29.95 (+0.11), COV: 92.44 (+0.83), EW: 120.92 (+0.64), MYL: 53.55 (+1.18), COO: 163.90 (+0.24), CG: 27.76 (+0.20), ABAX: 52.66 (+1.13), BAX: 70.14 (+0.08), DGX: 63.46 (-0.02), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78), HGR: 23.93 (+0.40)
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
ABMD: 32.79 (+1.44), BDX: 128.70 (+1.18), MDT: 68.16 (+0.73), ARAY: 6.33 (+0.11), NUVA: 40.90 (+1.64), CYBX: 52.50 (+1.77), BSX: 13.28 (+0.10), JNJ: 107.78 (+0.74), ICUI: 70.90 (unch), WMGI: 31.62 (-0.16), OPK: 8.35 (-0.04), RMD: 52.22 (+0.11), ABBV: 63.46 (+2.28), SYK: 87.53 (+0.49), ZMH: 111.24 (+1.96), ABT: 43.59 (+0.10), SMA: 9.90 (+0.16), BCR: 163.97 (+2.98), MCK: 203.41 (-0.07), TMO: 117.57 (+0.98), PFE: 29.95 (+0.11), COV: 92.44 (+0.83), EW: 120.92 (+0.64), MYL: 53.55 (+1.18), COO: 163.90 (+0.24), CG: 27.76 (+0.20), ABAX: 52.66 (+1.13), BAX: 70.14 (+0.08), DGX: 63.46 (-0.02), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78), HGR: 23.93 (+0.40)
MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews
ABMD: 32.79 (+1.44), BDX: 128.70 (+1.18), MDT: 68.16 (+0.73), ARAY: 6.33 (+0.11), NUVA: 40.90 (+1.64), CYBX: 52.50 (+1.77), BSX: 13.28 (+0.10), JNJ: 107.78 (+0.74), ICUI: 70.90 (unch), WMGI: 31.62 (-0.16), OPK: 8.35 (-0.04), RMD: 52.22 (+0.11), ABBV: 63.46 (+2.28), SYK: 87.53 (+0.49), ZMH: 111.24 (+1.96), ABT: 43.59 (+0.10), SMA: 9.90 (+0.16), BCR: 163.97 (+2.98), MCK: 203.41 (-0.07), TMO: 117.57 (+0.98), PFE: 29.95 (+0.11), COV: 92.44 (+0.83), EW: 120.92 (+0.64), MYL: 53.55 (+1.18), COO: 163.90 (+0.24), CG: 27.76 (+0.20), ABAX: 52.66 (+1.13), BAX: 70.14 (+0.08), DGX: 63.46 (-0.02), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78), HGR: 23.93 (+0.40)
9.9% Return Seen to Date on SmarTrend ABIOMED Call (ABMD)
Comtex SmarTrend(R) - Wed Aug 20, 10:04AM CDT
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on June 6th, 2014 at $23.28. In approximately 3 months, ABIOMED has returned 9.90% as of today's recent price of $25.58.
ABMD: 32.79 (+1.44)
Shares of ABMD Up 9.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Aug 12, 9:18AM CDT
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on June 6th, 2014 at $23.28. In approximately 2 months, ABIOMED has returned 9.52% as of today's recent price of $25.49.
ABMD: 32.79 (+1.44)
India Cardiovascular Devices Market Outlook and Trends 2014-2019
M2 - Wed Aug 06, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tz8hhr/india) has announced the addition of the "India Cardiovascular Devices Market Outlook and Trends Till 2019" report to their offering. The Market Intelligence report provides critical market data for India cardiovascular devices market and its product categories. The data includes market size in terms of value and volume; average selling price for each product type, growth trends and market shares of companies at sector and category level. It's vital cross category comparison and cross sub-category comparison section makes analysis very handy for company professionals. The report helps professionals in mapping market size, competition, understanding historic and future growth trends. It covers important categories such as cardiac assist devices, cardiac catheters and guidewires, cardiac rhythm management, cardiovascular heart valve and repair, cardiovascular monitoring systems, cardiovascular surgery, interventional cardiovascular devices, and peripheral vascular devices. Scope - Market Size - Market Growth - Competitive Analysis - Pricing Analysis - Recent Events and Developments Key Topics Covered: 1 Tables & Charts 2 Introduction 3 Scope of the Report 4 Indian Market for Cardiovascular Devices 5 Indian Market for Cardiac Assist Devices 6 Indian Market for Cardiac Catheters and Guidewires 7 Indian Market for Cardiac Rhythm Management 8 Indian Market for Cardiovascular Heart Valve and Repair 9 Indian Market for Cardiovascular Monitoring Systems 10 Indian Market for Cardiovascular Surgery 11 Indian Market for Interventional Cardiovascular Devices 12 Indian Market for Peripheral Vascular Devices 13 Recent Events and Developments 14 Appendix Companies Mentioned - Abbott Laboratories - ABIOMED, Inc. - Arrow International, Inc. - AtriCure, Inc. - Biosense Webster, Inc. - BIOTRONIK GmbH & Co. KG - Boston Scientific Corporation - C.R. Bard, Inc. - Cardiac Science Corporation - Cordis Corporation - Datascope Corp. - Edwards Lifesciences Corporation - ev3 Inc. - Fukuda Denshi Co., Ltd. - GE Healthcare - HEXACATH - MAQUET GmbH & Co. KG - Medtronic, Inc. - Nihon Kohden Corporation - OSI Systems, Inc. - Philips Medical Systems - Sahajanand Medical technologies Pvt. Ltd. - Shree Pacetronix Ltd. - Sorin Group - St. Jude Medical Inc. - Terumo Corporation - Thoratec Corporation - TTK Healthcare Limited - Vascular Concepts Limited - Welch Allyn Inc. For more information visit http://www.researchandmarkets.com/research/tz8hhr/india
ABT: 43.59 (+0.10), ABMD: 32.79 (+1.44), BCR: 163.97 (+2.98), MDT: 68.16 (+0.73), EW: 120.92 (+0.64), OSIS: 70.88 (+1.17), ATRC: 17.44 (+1.08), BSX: 13.28 (+0.10), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78)
Abiomed Falls, Sees Flat Fiscal Q1 Loss and Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 1:10PM CDT
For fiscal 2015, Abiomed (ABMD) reiterated its revenues guidance between $205 and $212 million, up 12 to 15% over the prior fiscal year.
ATEC: 1.52 (-0.05), ABMD: 32.79 (+1.44), ARAY: 6.33 (+0.11), HTWR: 77.12 (+0.98)
ABMD Recent Posts: http://investorshangout.com/Abiomed-ABMD-53201/
ABMD Abiomed Recent Headline News
Nasdaq stocks posting largest percentage increases
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
IMDZ: 30.99 (+1.39), ABMD: 32.79 (+1.44), BGFV: 12.31 (+0.29), RDCM: 8.60 (+0.10), AMED: 26.10 (+0.82), MRCY: 13.98 (-0.07), OMER: 16.57 (unch), ESBF: 18.66 (+0.07), EVOK: 6.70 (+0.76), IQNT: 16.83 (+1.10), KONA: 22.53 (+0.57), TQNT: 21.63 (+1.56), LAKE: 14.10 (-0.14), SAJA: 6.48 (-0.34)
Ocwen Financial Climbs Despite Earnings Shortfall
at The Street - Thu Oct 30, 4:20PM CDT
ABIOMED, Inc. (NASDAQ:ABMD), Calix Inc (NYSE:CALX) and Ocwen Financial Corp (NYSE:OCN) are today's top-gaining billionaire stock picks. In the red this Thursday are Yamana Gold Inc. (NYSE:AUY), Wes...
ABMD: 32.79 (+1.44), CALX: 10.81 (+0.05), OCN: 23.56 (+0.40), AUY: 3.98 (-0.48), WSTL: 1.34 (-0.09)
Abiomed tops Street 2Q forecasts
Automated Insights - Thu Oct 30, 7:28AM CDT
DANVERS, Mass. (AP) _ Abiomed Inc. (ABMD) on Thursday reported profit of $3.8 million in its fiscal second quarter.
ABMD: 32.79 (+1.44)
Abiomed Announces Second Quarter Fiscal 2015 Revenue of $51.9 Million, Up 17% Over Prior Year
GlobeNewswire - Thu Oct 30, 6:10AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reports second quarter fiscal 2015 revenue of $51.9 million, an increase of 17% compared to revenue of $44.3 million for the same period of fiscal 2014. Second quarter fiscal 2015 GAAP net income was $3.8 million or $0.09 per diluted share, compared to GAAP net income of $1.1 million or $0.03 per diluted share for the prior year period.
ABMD: 32.79 (+1.44)
Abiomed Second Quarter Fiscal 2015 Earnings and Conference Call Notification
GlobeNewswire - Thu Oct 09, 1:41PM CDT
Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, October 30, 2014, the Company will release financial results for the second quarter of fiscal 2015. The Company will host a conference call to discuss the results on Thursday, October 30, 2014, at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer; Robert L. Bowen, Vice President and Chief Financial Officer, will host the conference call.
ABMD: 32.79 (+1.44)
ABIOMED Up on Positive Impella RP Clinical Trial Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:02PM CDT
Data gathered at the end of the 30-day trial was encouraging and exhibited the high potential of ABIOMED, Inc.'s (ABMD) Impella RP in the treatment of RVF patients.
ATEC: 1.52 (-0.05), ABMD: 32.79 (+1.44), RTIX: 5.09 (+0.33), ERB: 3.08 (unch)
Abiomed Appoints Ingrid Goldberg as Director of Investor Relations
GlobeNewswire - Thu Sep 18, 9:34AM CDT
Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the appointment of Ingrid Goldberg, as Director of Investor Relations.
ABMD: 32.79 (+1.44)
Clinical Trial Results for Impella RP Right Ventricular Heart Failure Trial, RECOVER RIGHT, Released at TCT 2014
GlobeNewswire - Tue Sep 16, 4:03PM CDT
Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP(TM) (Right Percutaneous) System. The clinical trial results demonstrated a survival rate of 73% in the overall patient population.
ABMD: 32.79 (+1.44)
Data From RECOVER RIGHT Impella RP Trial to be Announced at TCT 2014
GlobeNewswire - Wed Sep 10, 7:39AM CDT
Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced that data from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP(TM) (Right Peripheral) System, will be released during the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2014 scientific meeting.
ABMD: 32.79 (+1.44)
Abiomed to Present at the Morgan Stanley Global Healthcare Conference 2014
GlobeNewswire - Wed Sep 03, 7:08AM CDT
Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on September 10, 2014 at 10:20 a.m. EDT. The conference will be held at the Grand Hyatt New York in New York, NY.
ABMD: 32.79 (+1.44), MS: 34.95 (+0.43)
10.4% Return Seen to Date on SmarTrend ABIOMED Call (ABMD)
Comtex SmarTrend(R) - Wed Aug 27, 11:29AM CDT
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on June 6th, 2014 at $23.28. In approximately 3 months, ABIOMED has returned 10.38% as of today's recent price of $25.69.
ABMD: 32.79 (+1.44)
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Industry Outlook
ABMD: 32.79 (+1.44), BDX: 128.70 (+1.18), MDT: 68.16 (+0.73), ARAY: 6.33 (+0.11), NUVA: 40.90 (+1.64), CYBX: 52.50 (+1.77), BSX: 13.28 (+0.10), JNJ: 107.78 (+0.74), ICUI: 70.90 (unch), WMGI: 31.62 (-0.16), OPK: 8.35 (-0.04), RMD: 52.22 (+0.11), ABBV: 63.46 (+2.28), SYK: 87.53 (+0.49), ZMH: 111.24 (+1.96), ABT: 43.59 (+0.10), SMA: 9.90 (+0.16), BCR: 163.97 (+2.98), MCK: 203.41 (-0.07), TMO: 117.57 (+0.98), PFE: 29.95 (+0.11), COV: 92.44 (+0.83), EW: 120.92 (+0.64), MYL: 53.55 (+1.18), COO: 163.90 (+0.24), CG: 27.76 (+0.20), ABAX: 52.66 (+1.13), BAX: 70.14 (+0.08), DGX: 63.46 (-0.02), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78), HGR: 23.93 (+0.40)
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Investment Ideas
ABMD: 32.79 (+1.44), BDX: 128.70 (+1.18), MDT: 68.16 (+0.73), ARAY: 6.33 (+0.11), NUVA: 40.90 (+1.64), CYBX: 52.50 (+1.77), BSX: 13.28 (+0.10), JNJ: 107.78 (+0.74), ICUI: 70.90 (unch), WMGI: 31.62 (-0.16), OPK: 8.35 (-0.04), RMD: 52.22 (+0.11), ABBV: 63.46 (+2.28), SYK: 87.53 (+0.49), ZMH: 111.24 (+1.96), ABT: 43.59 (+0.10), SMA: 9.90 (+0.16), BCR: 163.97 (+2.98), MCK: 203.41 (-0.07), TMO: 117.57 (+0.98), PFE: 29.95 (+0.11), COV: 92.44 (+0.83), EW: 120.92 (+0.64), MYL: 53.55 (+1.18), COO: 163.90 (+0.24), CG: 27.76 (+0.20), ABAX: 52.66 (+1.13), BAX: 70.14 (+0.08), DGX: 63.46 (-0.02), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78), HGR: 23.93 (+0.40)
MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 3:31AM CDT
MedTech Defies Sequestration, M&As Steal the Show - Zacks Analyst Interviews
ABMD: 32.79 (+1.44), BDX: 128.70 (+1.18), MDT: 68.16 (+0.73), ARAY: 6.33 (+0.11), NUVA: 40.90 (+1.64), CYBX: 52.50 (+1.77), BSX: 13.28 (+0.10), JNJ: 107.78 (+0.74), ICUI: 70.90 (unch), WMGI: 31.62 (-0.16), OPK: 8.35 (-0.04), RMD: 52.22 (+0.11), ABBV: 63.46 (+2.28), SYK: 87.53 (+0.49), ZMH: 111.24 (+1.96), ABT: 43.59 (+0.10), SMA: 9.90 (+0.16), BCR: 163.97 (+2.98), MCK: 203.41 (-0.07), TMO: 117.57 (+0.98), PFE: 29.95 (+0.11), COV: 92.44 (+0.83), EW: 120.92 (+0.64), MYL: 53.55 (+1.18), COO: 163.90 (+0.24), CG: 27.76 (+0.20), ABAX: 52.66 (+1.13), BAX: 70.14 (+0.08), DGX: 63.46 (-0.02), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78), HGR: 23.93 (+0.40)
9.9% Return Seen to Date on SmarTrend ABIOMED Call (ABMD)
Comtex SmarTrend(R) - Wed Aug 20, 10:04AM CDT
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on June 6th, 2014 at $23.28. In approximately 3 months, ABIOMED has returned 9.90% as of today's recent price of $25.58.
ABMD: 32.79 (+1.44)
Shares of ABMD Up 9.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Aug 12, 9:18AM CDT
SmarTrend identified an Uptrend for ABIOMED (NASDAQ:ABMD) on June 6th, 2014 at $23.28. In approximately 2 months, ABIOMED has returned 9.52% as of today's recent price of $25.49.
ABMD: 32.79 (+1.44)
India Cardiovascular Devices Market Outlook and Trends 2014-2019
M2 - Wed Aug 06, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tz8hhr/india) has announced the addition of the "India Cardiovascular Devices Market Outlook and Trends Till 2019" report to their offering. The Market Intelligence report provides critical market data for India cardiovascular devices market and its product categories. The data includes market size in terms of value and volume; average selling price for each product type, growth trends and market shares of companies at sector and category level. It's vital cross category comparison and cross sub-category comparison section makes analysis very handy for company professionals. The report helps professionals in mapping market size, competition, understanding historic and future growth trends. It covers important categories such as cardiac assist devices, cardiac catheters and guidewires, cardiac rhythm management, cardiovascular heart valve and repair, cardiovascular monitoring systems, cardiovascular surgery, interventional cardiovascular devices, and peripheral vascular devices. Scope - Market Size - Market Growth - Competitive Analysis - Pricing Analysis - Recent Events and Developments Key Topics Covered: 1 Tables & Charts 2 Introduction 3 Scope of the Report 4 Indian Market for Cardiovascular Devices 5 Indian Market for Cardiac Assist Devices 6 Indian Market for Cardiac Catheters and Guidewires 7 Indian Market for Cardiac Rhythm Management 8 Indian Market for Cardiovascular Heart Valve and Repair 9 Indian Market for Cardiovascular Monitoring Systems 10 Indian Market for Cardiovascular Surgery 11 Indian Market for Interventional Cardiovascular Devices 12 Indian Market for Peripheral Vascular Devices 13 Recent Events and Developments 14 Appendix Companies Mentioned - Abbott Laboratories - ABIOMED, Inc. - Arrow International, Inc. - AtriCure, Inc. - Biosense Webster, Inc. - BIOTRONIK GmbH & Co. KG - Boston Scientific Corporation - C.R. Bard, Inc. - Cardiac Science Corporation - Cordis Corporation - Datascope Corp. - Edwards Lifesciences Corporation - ev3 Inc. - Fukuda Denshi Co., Ltd. - GE Healthcare - HEXACATH - MAQUET GmbH & Co. KG - Medtronic, Inc. - Nihon Kohden Corporation - OSI Systems, Inc. - Philips Medical Systems - Sahajanand Medical technologies Pvt. Ltd. - Shree Pacetronix Ltd. - Sorin Group - St. Jude Medical Inc. - Terumo Corporation - Thoratec Corporation - TTK Healthcare Limited - Vascular Concepts Limited - Welch Allyn Inc. For more information visit http://www.researchandmarkets.com/research/tz8hhr/india
ABT: 43.59 (+0.10), ABMD: 32.79 (+1.44), BCR: 163.97 (+2.98), MDT: 68.16 (+0.73), EW: 120.92 (+0.64), OSIS: 70.88 (+1.17), ATRC: 17.44 (+1.08), BSX: 13.28 (+0.10), STJ: 64.17 (-0.11), THOR: 27.18 (+0.78)
Abiomed Falls, Sees Flat Fiscal Q1 Loss and Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 1:10PM CDT
For fiscal 2015, Abiomed (ABMD) reiterated its revenues guidance between $205 and $212 million, up 12 to 15% over the prior fiscal year.
ATEC: 1.52 (-0.05), ABMD: 32.79 (+1.44), ARAY: 6.33 (+0.11), HTWR: 77.12 (+0.98)
(0)
(0)Abiomed (ABMD) Stock Research Links
Scroll down for more posts ▼